Format

Send to

Choose Destination
J Clin Invest. 2013 Aug;123(8):3190-200. doi: 10.1172/JCI70212. Epub 2013 Aug 1.

Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.

Author information

1
Vesalius Research Center, University of Leuven, Leuven, Belgium.

Abstract

Four decades ago, angiogenesis was recognized as a therapeutic target for blocking cancer growth. Because of its importance, VEGF has been at the center stage of antiangiogenic therapy. Now, several years after FDA approval of an anti-VEGF antibody as the first antiangiogenic agent, many patients with cancer and ocular neovascularization have benefited from VEGF-targeted therapy; however, this anticancer strategy is challenged by insufficient efficacy, intrinsic refractoriness, and resistance. Here, we examine recent discoveries of new mechanisms underlying angiogenesis, discuss successes and challenges of current antiangiogenic therapy, and highlight emerging antiangiogenic paradigms.

PMID:
23908119
PMCID:
PMC3726176
DOI:
10.1172/JCI70212
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center